Ascentage Pharma Group International Future Growth
Future criteria checks 3/6
Ascentage Pharma Group International is forecast to grow earnings and revenue by 52.2% and 25.8% per annum respectively. EPS is expected to grow by 53.9% per annum. Return on equity is forecast to be 419.2% in 3 years.
Key information
52.2%
Earnings growth rate
53.9%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 25.8% |
| Future return on equity | 419.2% |
| Analyst coverage | Low |
| Last updated | 20 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,226 | 713 | 860 | 734 | 5 |
| 12/31/2025 | 511 | -894 | -854 | -727 | 5 |
| 12/31/2024 | 994 | -327 | -393 | -262 | 5 |
| 6/30/2024 | 903 | -360 | -751 | -712 | N/A |
| 3/31/2024 | 563 | -643 | -767 | -719 | N/A |
| 12/31/2023 | 222 | -926 | -783 | -726 | N/A |
| 9/30/2023 | 239 | -902 | -798 | -707 | N/A |
| 6/30/2023 | 257 | -879 | -814 | -687 | N/A |
| 3/31/2023 | 233 | -881 | -852 | -671 | N/A |
| 12/31/2022 | 210 | -883 | -891 | -654 | N/A |
| 9/30/2022 | 160 | -848 | -922 | -620 | N/A |
| 6/30/2022 | 111 | -812 | -954 | -586 | N/A |
| 3/31/2022 | 69 | -797 | -997 | -595 | N/A |
| 12/31/2021 | 28 | -782 | -1,041 | -605 | N/A |
| 9/30/2021 | 25 | -759 | -1,021 | -635 | N/A |
| 6/30/2021 | 23 | -735 | -1,000 | -665 | N/A |
| 3/31/2021 | 18 | -706 | -931 | -637 | N/A |
| 12/31/2020 | 12 | -678 | -861 | -610 | N/A |
| 9/30/2020 | 14 | -922 | -798 | -576 | N/A |
| 6/30/2020 | 15 | -1,167 | -735 | -542 | N/A |
| 3/31/2020 | 15 | -1,324 | -638 | -501 | N/A |
| 12/31/2019 | 15 | -1,481 | -542 | -460 | N/A |
| 9/30/2019 | 11 | -1,171 | -454 | -399 | N/A |
| 6/30/2019 | 7 | -862 | -366 | -338 | N/A |
| 3/31/2019 | 7 | -604 | -310 | -288 | N/A |
| 12/31/2018 | 7 | -345 | -253 | -238 | N/A |
| 12/31/2017 | 6 | -119 | N/A | -108 | N/A |
| 12/31/2016 | 8 | -108 | N/A | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6855 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6855 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6855 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6855's revenue (25.8% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).
High Growth Revenue: 6855's revenue (25.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6855's Return on Equity is forecast to be very high in 3 years time (419.2%).